HOW TO USE THIS INDEX

The Surgeon General's Report on Smoking and Health consists of 23
chapters and an Appendix. Each includes a detailed table of contents to lead
the reader to the information sought and to give a quick overview of content.

The index reflects the contents of all 23 chapters and the Appendix. It
was attempted to use the natural language of the Report whenever possible.
but to achieve consistency in the terminology. some concepts had to be
reworded.

Major concepts are expressed in primary terms (in bold, all upper case
letters), which are modified by the secondary terms (indented. lower case.
followed by page numbers), in order to convey the specific topic. In order to
lead the reader to primary terms related to the one of interest. cross
references follow many primary terms, e.g.

ALLERGY
(See also ALLERGY, TOBACCO;
HYPERSENSITIVITY)

If a certain concept could have appeared as more than one primary
term, the reader is referred to the primary term actually used in the following
manner:

Areca nut
See BETEL NUT

Secondary terms are followed by the pagination. The latter consists of
one bold figure, referring to the Report chapter, a colon, followed by the page
number(s). The following examples illustrate this:

chapter t
ADOLESCENTS

antismoking education, {17}: [6 pm page(s)

attitudes toward smoking, 17:5-6, 17:8-10

 

 

 

 

17:6 (This entry refers to Chapter 17, page 6.)

17:9-12, 18:7, A:6-9 (This entry refers to Chapter 17,
pages 9-12; Chapter 18. page 7; and Appendix, pages
6-9.)
INDEX

ABORTION
in female tobacco workers, 8:9
maternal smoking and, 8:9, 8:30-32
relative risk for smokers vs. non-
smokers, 8:31-32
research needs, 8:77
in smokers vs. nonsmokers, 8:30-32
smoking and wanted vs. unwanted
pregnancy and, 8:30-32
ABRUPTIO PLACENTAE
gestational age and risk in smoking
vs. nonsmoking mothers, 8:44,
8:46
maternal smoking and, 8:39
smoking and stillbirth, 8:39
smoking levels and, 8:39
smoking levels and perinatal mortali-
ty, 8:40
ABSENTEEISM
effect of smoking, 3:8, 3:10
effect of smoking, summary of find-
ings, 1:12-18
smokers vs. nonsmokers vs. ex-smok-
ers, 3:8, 3:12-14
ABSORPTION
nicotine, 14:85
toxic elements in respiratory tract,
14:98
ABSTINENCE
males vs. females, 15:28
smoking habit and, 15:26
Abstinence syndrome
See TOBACCO WITHDRAWAL
SYNDROME
ACADEMIC ACHIEVEMENT
smoking and, 17:16, 20:8
Teenage Self Test scores and, 20:22
ACCIDENTS
smoking on the job and, 7:15
ACROLEIN
eye and nose irritation and, 11:26
humectants and, 14:63

levels, effect of smoking in enclosed
spaces, 11:25
Adenoma
See NEOPLASMS
ADDICTION
(See also HABITUATION)
cessation of smoking and, 18:22
identification of addicted smokers,
18:13
laboratory models, 16:12
to nicotine, 16:7-9, 18:12
smoking vs. drug addiction, 16:10-11
ADOLESCENTS
(See also TEENAGERS)
antismoking education, 17:6, 17:17-22,
20:5-26, 21:25
attitudes toward smoking, 17:5-6,
17:8-10
cessation of smoking, 18:19
drug abuse and smoking, 17:23, 18:14
effect of school smoking policies,
23:8-12
illegality of tobacco use, 23:7
influence of role models, 21:11-14
recommendations for prevention of
smoking, 17:22-25
smoking habit, 17:7-8, 18:16, 23:9
smoking habit in males vs. females
in the United States, 19:21
social factors in smoking initiation,
17:12-17
Adrenaline
See CATECHOLAMINES
ADULT EDUCATION
Adult Basic Education, 21:7, 21:9
Adult Performance Level Program,
21:7-9
antismoking education, 21:10-11,
21:22-26
participation statistics, 21:5-6
ADULTS
cigarette consumption patterns in the
United States, A:23
increase of cigarette consumption
over time, A:17
patterns of smoking prevalence,
A:li, A:12-14
self-reported smoking characteristics,
A:21-22
smoking prevalence by educational
level, A:14-16
smoking prevalence by family in-
come, A:14-16
smoking surveys in the United
States, A:8-10, A:18
ADVERTISING
antismoking information, 19:9, 21:15
effect on smoking rates, 18:22-23,
21:23
effect on youth, 17:5-6, 17:15, 17:22,
20:6-7
Federal Communications Commission
rules, A:7
lung disease campaign, 21:10
restrictions in Denmark, 18:22, 22:6
revenues from tobacco interests,
21:18
ADVERTISING BAN
effect on consumption in Great Brit-
ain, 18:22-23
effect on consumption in Ireland,
18:22
effect on consumption in Italy, 18:22
effect on consumption in New Zea-
land, 18:22
effect on consumption in the United
States, 18:23
effect on per capita consumption,
A:8
ADVISORY COMMITTEE TO THE
SURGEON GENERAL ON SMOK-
ING AND HEALTH
summary of 1964 Report, 1:7-9
summary of 1979 Report, 1:10-35
AFLATOXIN B;
as tobacco contaminant, 14:22
AGE
initiation of smoking and, 17:8-9
motivation for smoking and, 18:11
recidivism and, 19:31
AGE GROUPS
absenteeism and, 3:18
bed disability and, 3:12

cessation of smoking and, 3:18
heart conditions and, 3:19
mortality ratio, 2:17
mortality ratio, mortality rates and
excess deaths in the United
States, 2:11
percent distribution of cigar, ciga-
rette and pipe smokers in the
United States, 13:9
AGING
(See also TOBACCO AGING)
atherosclerosis in smokers vs. non-
smokers and, 4:12, 4:14
effect on antipyrine pharmacokinetics
in smokers vs. nonsmokers,
12:29-30
Agricultural chemicals
See PESTICIDES
AIR POLLUTION
bronchopulmonary diseases and, 1:19
chronic obstructive lung disease and,
6:36
in lung neoplasm etiology, 5:25-27
lung pathology in smokers vs. non-
smokers and, 6:36-37
smoking and chronic obstructive lung
disease and, 6:37-38
smoking and respiratory symptoms
and, 6:37
AIRPLANES
effect of smoking on nonsmokers,
11:26
ALBANY CIVIL SERVANT STUDY
angina pectoris, 4:46
sudden cardiac death, 4:43
ALCOHOL
and benzo(a)pyrene in esophageal
neoplasm induction in animals,
5:44
content of cigarette smoke, 14:42
pharmacokinetics in smokers vs. non-
smokers, 12:39
ALCOHOL CONSUMPTION
beer, and motivation for smoking,
18:11
cessation of smoking and, 18:20
effect on esophagus, 13:25
interactive effect with smoking on
atherosclerosis, 4:18, 4:15
smoking, coffee drinking and peptic
ulcer and, 9:6
smoking and laryngeal neoplasms
and, 5:32, 5:34
smoking and oral neoplasms and,
5:40-41
smoking in esophageal neoplasm eti-
ology and, 5:43-44
smoking rate and, 16:13, 18:14
ALDEHYDES
(See also ACROLEIN)
content of cigarette smoke, 14:42
humectants and, 14:63
ALKALOID CONTENT
(See also NICOTINE CONTENT)
in cigar vs. cigarette smoke conden-
sate, 13:11
reduction in particulate phase ciga-
rette smoke, 14:108
ALKALOIDS, TOBACCO
(See also COTININE; NICOTINE;
NORNICOTINE)
pharmacological activity, 14:93
relative molar potency in cigarette
smoke, 14:96
structural formulae, 14:46
ALKANE CONTENT
in cigarette smoke, 14:45
ALKENES
in cigarette smoke, 14:48
ALLERGIC RHINITIS
passive smoking and, 10:21
smoking and, 10:20
ALLERGY
(See also ALLERGY, TOBACCO;
HYPERSENSITIVITY)
childhood respiratory infections and,
10:12
clinical manifestations, 10:20
definition, 10:8-9
diagnosis, 10:5 -
effect of tobacco smoke exposure,
10:14
involuntary smoking and, 11:31
nicotine in induction of, 10:22
predisposition, and broncho-constric-
tion and chest infections, 10:22
skin test reactions to tobacco leaf
extracts in smokers vs. nonsmok-
ers, 10:13
smoking and, summary of findings,
1:23-24
thromboangiitis obliterans and, 4:60
tobacco and tobacco smoke in etiolo-
gy of, 10:5, 10:28-24
tobacco smoke as secondary factor,
10:8

ALLERGY, TOBACCO
asthma and, 10:21
basic mechanisms, 10:5
cardiovascular diseases and, 10:22-23
diagnosis, 10:24
diagnostic criteria, 10:6-7
epidemiology, 10:12-14
tests, 10:6
treatment and prevention, 10:24
Alveolar macrophages
See MACROPHAGES, ALVEOLAR
AMBIENT AIR QUALITY STAN-
DARD
smoking in enclosed spaces and,
11:21
AMBLYOPIA, TOBACCO
etiology, 12:66
AMERICAN ASSOCIATION FOR
HEALTH, PHYSICAL EDUCA-
TION, AND RECREATION
recommendations for school pro-
grams, 17:15
statement on school smoking policies,
23:8-9, 23:13-14
training of health educators, 23:32
AMERICAN CANCER SOCIETY
campaign against hospital cigarette
sales, 22:20
group cessation program, 19:10
study of physicians’ smoking habits,
22:11
survey of teachers’ smoking habits
and attitudes, 17:15, 21:13
withdrawal clinics, 21:16
youth antismoking programs, 20:22
youth smoking studies, 17:8, 18:15,
21:11-12
AMERICAN DENTAL ASSOCIATION
schoo] programs on oral health, 20:23
AMERICAN HEALTH FOUNDATION
cessation program, 21:16
“Know Your Body” program, 21:20
AMERICAN HEART ASSOCIATION
adolescent antismoking demonstration
projects, 20:22
withdrawal clinics, 21:16
AMERICAN LUNG ASSOCIATION
antismoking curriculum models,
20:22-23
withdrawal clinics, 21:16
AMERICAN MEDICAL ASSOCIATION
antismoking advice to patients, 22:16
AMERICAN PHARMACEUTICAL AS-
SOCIATION
recommendation against cigarette
sales, 22:9
AMERICAN PUBLIC HEALTH ASSO.
CIATION
members’ smoking attitudes, 22:7,
22:15
AMERICAN SCHOOL HEALTH AS-
SOCIATION
state school health programs survey,
23:5-23-7
AMINES
bladder neoplasms and, 14:47
content in cigarette smoke, 14:41,
14:47
content in tobacco and tobacco
smoke, 12:74
AMMONIA CONTENT
in cigar smoke, 14:39
in cigarette smoke, 14:39
in sidestream smoke, 14:41
Amount smoked
See SMOKING LEVELS; CIGA-
RETTE CONSUMPTION
ANALYTICAL METHODS
fiber optic probe system, 14:9
Thermal Energy Analyzer, 14:9
ANGINA PECTORIS
(See also CORONARY HEART
DISEASE)
clinical features and prognosis, 4:46
effect of carbon monoxide and nico-
tine, 4:47
effect of involuntary smoking, 11:30-
31
effect of low level carbon monoxide
exposure, 11:30, 11:34
effect of nicotine, 4:39
effect of smoking, 4:47
morbidity ratio, effect of smoking
levels, 4:48
morbidity ratio in smokers vs. non-
smokers, 4:48
research needs, 4:47, 4:49
ANIMAL MODELS
atherosclerosis, 4:9, 4:16-18
cerebrovascular disease, 4:49-50
esophageal neoplasms, 5:44
laryngeal neoplasms, 5:34-35
lung neoplasms, 29:31
myocardial infarction, 4:20, 4:40
oral neoplasms, 41-42

pancreatic neoplasms, 5:51-53
peripheral vascular disease, 4:53
sudden cardiac death, 4:48
tobacco induced carcinogenesis, 5:53-
54
tobacco induced carcinogenesis, sum-
mary of methods, 5:29-30
ANNOYANCE
effect of involuntary smoking in
nonsmokers, 11:25
smoking in public transportation and,
11:34
ANOXIA
maternal smoking and infant mortal-
ity, 8:47
ANTEPARTUM HEMORRHAGE
maternal smoking and, 8:39
ANTICOAGULANTS
effect of smoking on metabolism,
12:54-55
ANTIGEN-ANTIBODY REACTIONS
effect of cigarette smoke in mice,
12:59
response to viral vaccines in smokers
vs. nonsmokers, 12:58-59
ANTIPYRINE
clearance in lung neoplasm patients,
12:31
pharmacokinetics in sMokers vs. non-
smokers, 12:29-31
ANTIGENS
identification in tobacco leaf and
smoke, 10:11
tobacco proteins, 10:11
ANTISMOKING CAMPAIGNS
(See also CESSATION OF SMOK-
ING; PREVENTION OF SMOK-
ING)
absenteeism and, 3:8
in asbestos plants, 7:12
in coal miners, 7:15
education in Winnipeg schools, 20:18
education of youth in Great Britain,
20:10
effect on per capita consumption,
AT
effect on youth, 17:17-18
effectiveness, 18:23, 19:9-10
German youth, 20:8-9
hospital smoking policy guidelines in
Canada, 22:20-21
hospital smoking policy guidelines in
Great Britain, 22:20
hospital smoking policy guidelines in
Scotland, 22:21
in occupational settings, 7:18-19
Women’s Christian Temperance
Union, 23:12-13
youth to youth programs, 20:9
ANTISMOKING MATERIALS
posters, 19:9
in school programs, 20:8, 20:7-15,
20:17
ANTISOCIAL TENDENCIES
smoking habit and, 18:9
ANTITOBACCO CHEWING GUM
in smoking reduction, 19:17
ANTITRYPSIN DEFICIENCY
bronchopulmonary diseases and, 1:19
in emphysema etiology, 6:33-34
risk for chronic obstructive lung dis-
ease, 6:33-34
ANXIETY
(See also STRESS;
NEUROTICISM)
in deprived smokers, 16:7-8
reduction by smoking, 16:11
smoking habits in medical students
and, 18:8
AORTIC ANEURYSM
clinical and histopathological fea-
tures, 4:55
coronary heart disease and, 4:55
mortality ratios, effect of smoking
levels, 4:55
research needs, 4:56
smoking in etiology of, 4:56
Areca chewing
See BETEL CHEWING; TOBACCO
CHEWING
Areca nut
See BETEL NUT
AROMATIC AMINES
(See also HETEROCYCLIC COM-
POUNDS; NAPHTHYLAMINES)
bladder neoplasms and, 5:47
occupational hazards, 7:16
smoking and occupational risk of
bladder neoplasms, 7:16
AROMATIC HYDROCARBONS
(See also BENZANTHRACENES,
BENZO(a)PYRENE; METHYL-
CHOLANTHRENE)
aryl hydrocarbon hydroxylase activity
in fetus after maternal exposure
in rats, 8:66

benzo(a)pyrene as indicator of carci-
nogenic potential of cigarette
smoke, 14:109-110
in cigarette smoke, 14:41-42, 14:51,
14:54
in cigarette vs. cigar vs. pipe smoke,
13:11-12
as cocarcinogens, 14:52
effect of increased tobacco combusti-
bility on reduction, 14:111
effect on caffeine pharmacokinetics
in rats, 12:32-33
effect on cytochrome P,;-450 induc-
tien, 12:7-8
effect on cytochrome P,-450 synthe-
sis, 12:16-20
effect on drug metabolism, 12:7-9
effect on enzyme activity, 12:7-9
effect on enzyme activity in micro-
somes, 12:76
effect on liver function, 12:7-8
incomplete combustion and, 14:49
maternal-fetal exchange in animals,
8:66
reduction in particulate phase ciga-
rette smoke, 14:109
structural formulae, 14:53
AROUSAL
effect of nicotine, 15:11
ARSENIC CONTENT
in mainstream cigarette smoke, 14:59
ARTERIES
effect of carbon monoxide and nico-
tine in animals, 4:56
effect of smoking on atherosclerosis
in distal aorta and iliac arteries,
4:53
hyaline thickening in myocardium in
smokers vs. nonsmokers, 4:16
ARTERIOLES
effect of smoke inhalation in dogs,
4:18
hyaline thickening in myocardium in
smokers vs. nonsmokers, 4:16
Arteriosclerosis
See ATHEROSCLEROSIS
ARTIFICIAL SWEETENERS
bladder neoplasms and, 5:47
ARYL HYDROCARBON HYDROXYL-
ASE
(See also ENZYMES)
activity, 12:7-9
effect of benzo(a)pyrene or cigarette
smoke on activity in rats, 12:29
effect of cessation of smoking on
activity, 12:41
effect of cigarette smoke on activity
in liver vs. lung, 12:76
effect of smoking on activity, 5:57
fetal, activity after maternal aromat-
ic hydrocarbon exposure in rats,
8:66
inducibility in laryngeal and lung
neoplasm patients, 5:57
role in antipyrine pharmacokinetics,
12:30-31
role in drug metabolism, 12:7-9
ASBESTOS
occupational hazards, 7:11-13
smoking and laryngeal neoplasms
and, 5:34
and smoking in lung neoplasm etiolo-
gy, 5:28
ASBESTOSIS
(See also OCCUPATIONAL DIS-
EASES)
smoking and, 7:11-18
Ascorbic acid
See VITAMIN C
ASPHYXIA
in infants of smokers vs. nonsmok-
ers, 8:69
ASPIRIN
consumption in smokers vs. nonsmok-
ers, 18:13
ASTHMA
(See also RESPIRATORY TRACT
DISEASES)
effect of smoking in patients, 10:22
passive smoking and, 10:21
tobacco allergy and, 10:21
in tobacco workers, 10:21
ATHEROSCLEROSIS
alcohol consumption and smoking
and, 4:15
carbon monoxide and, 4:18
in cardiovascular disease etiology, 4:8
in coronary heart disease etiology,
4:7
effect of aleohol consumption and
smoking levels, 4:13
effect of carbon monoxide in choles-
terol fed animals, 4:17
effect of smoking levels, 4:8-16

experimental induction in animals,
4:9, 4:16-18
histology and pathogenesis, 4:7-10
in myocardial infarct etiology, 4:19-
20
nicotine and, 14:79
research needs, 4:18
risk factors, 4:8-9
smokers vs. nonsmokers, 4:10-16
somatic cell mutation theory of
pathogenesis, 4:10
thromboangiitis obliterans and, 4:60
ATHLETIC PERFORMANCE
smoking and, 20:8
ATTITUDES
(See also BEHAVIOR)
cessation of smoking and, 18:22
drug abuse, 18:10
parents, 17:13-14
teachers, 20:28, 21:12-13
youth, 17:5-6, 17:8, 17:10, 17:17,
17:28, 20:6, 20-13-14, 20:17-18,
20:21, 20:23, 21:11-12
AVERSIVE THERAPY
in cessation of smoking, 16:15-16
covert sensitization, 19:28
electric shock, 19:23
medical risks, 19:25-26
in multicomponent treatments, 19:19,
19:27, 19:30
rapid smoking, 19:24-26
satiation, 19:25-26
Schick Smoking Control Centers,
21:16
Aza-arenes
See HETEROCYCLIC COM-
POUNDS

BEHAVIOR
(See also ATTITUDES; MOTIVA-
TION; PERSONALITY)
effect of maternal smoking on chil-
dren, 1:21
effect on pharmacokinetics, 12:40-41
smoking habit and, summary of find-
ings, 1:32-33
BEHAVIOR, ANIMAL
effect of nicotine, 15:16
effect of nicotine in monkeys, 15:12
effect of nicotine in rats, 15:11,
15:18
BEHAVIOR MODIFICATION
(See also AVERSIVE THERAPY;
STIMULUS CONTROL TREAT-
MENT; CONTINGENCY CON-
TRACTING; MULTICOMPONENT
TREATMENT)
in cessation of smoking, 16:15-18,
19:19-29
BENZANTHRACENES
(See also AROMATIC HYDROCAR-
BONS)
in oral neoplasm induction in ham-
sters, 5:42
BENZENE
threshold limit values, 14:51
tobacco pyrolysis and, 14:49
BENZO(a)PYRENE
(See also AROMATIC HYDROCAR-
BONS)
as aromatic hydrocarbon indicator in
cigarette smoke, 14:109-110
effect on caffeine pharmacokinetics
in rats, 12:32-33
effect on fetus, research needs, 8:81
effect on maternal and fetal aryl
hydrocarbon hydroxylase activity
in rats, 8:66
effect on phenacetin pharmacokinet-
ics in rats, 12:59
effect on warfarin pharmacokinetics
in rats, 12:38
and ethanol in esophageal neoplasm
induction in animals, 5:44
in laryngeal neoplasm induction in
hamsters, 5:34-35
in lung neoplasm induction in ham-
sters, 5:30
maternal-fetal exchange in animals,
8:66
neoplasms in progeny after maternal
exposure in mice, 8:67
in oral neoplasm induction in ham-
sters, 5:42
reduction methods, 14:114
structural formula, 14:53
BENZO(a)PYRENE CONTENT
in cigar vs. cigarette vs. pipe smoke,
13:11-12
in cigarette smoke condensate, 14:112
effect of smoking in enclosed spaces,
11:24

BERKELEY CHILD HEALTH AND
DEVELOPMENT STUDIES, 8:14
Berkeley Project
See SCHOOL HEALTH CURRICU-
LUM PROJECT
BETA-ADRENERGIC BLOCKING
AGENTS
interactive effect with cigarette
smoke on airways, 12:54
interactive effect with cigarette
smoke on cardiovascular system,
12:53-54
BETA-NAPHTHYLAMINE
occupational hazards, 7:16
BETEL CHEWING
(See also TOBACCO CHEWING)
leukoplakia and, 5:41
in oral neoplasm etiology, 13:40-41
BETEL NUT
use in chewing tobacco, 13:39
BICARBONATE LEVELS
in infants of smokers vs. nonsmok-
ers, 8:69
BILIRUBIN LEVELS
effect of maternal smoking on neo-
nate, 12:34
smokers vs. nonsmokers, 12:34
BIOASSAY
ciliatoxie agents and, 14:105
in determining biological effects of
tobacco leaf characteristics, 14:23,
14:25
in determining physiological response
to cigarette smoke, 14:73
relationship of tobacco leaf charac-
teristics, smoke constituents and
biological response, 14-22-23
BIRTH WEIGHT
(See also FETAL GROWTH)
effect of carbon monoxide exposure
in pregnant rats, 8:60, 14:79
effect of impaired protein metabo-
lism in smoking mothers, 12:65-
66
effect of maternal injection of nico-
tine in animals, 8:53
effect of maternal smoking, 8:9,
8:11-18, 8:17, 8:20-21
effect of maternal smoking, research
needs, 8:78
effect of maternal smoking, summa-
ry of findings, 1:21
effect of maternal smoking and bio-
logic and socioeconomic factors,
8:14-15
effect of maternal smoking and ges-
tational age, 8:19-20
effect of maternal smoking and
weight gain, 8:25
effect of tobacco smoke in animals,
8:52
infant mortality in smokers vs. non-
smokers and, 8:29
infants of future smokers, smokers,
nonsmokers, and ex-smokers,
8:26-27
BLADDER NEOPLASMS
amines and, 14:47
artificial sweeteners and, 5:47
correlation with pancreatic neo-
plasms, 5:47
male vs. female smokers, 5:45-47
mortality ratio in smokers, 5:45-46
risk in ex-smokers, 5:46
smoking and occupational exposure
and, 5:47
smoking and occupational exposure
to aromatic amines and, 7:16
smoking and radiation and, 12:90
smoking and, summary of findings,
1:17
smoking in coal gas workers and,
7:16
smoking in etiology of, 5:45-47
BLOOD CHEMICAL ANALYSIS
albumin, creatinine and uric acid lev-
els in smokers vs. nonsmokers,
12:40, 12:84
effect of cessation of smoking, 12:87
effect of smoking, summary of find-
ings, 1:26
BLOOD CHOLESTEROL LEVELS
in atherosclerosis induction in ani-
mals, 4:9
in cigarette vs. cigar vs. pipe smok-
ers, 4:61, 13:34
coronary heart disease and, 4:61-62
effect of carbon monoxide in ani-
mals, 4:17, 61
effect of smoking levels, 4:62
smokers vs. nonsmokers, 4:61-62
in smokers vs. nonsmokers vs. ex-
smokers, 12:83-84

BLOOD CIRCULATION
(See also HEMODYNAMICS)
effect of smoking, 4:54
in maintenance of smoking habit,
15:19-20
smokers vs. nonsmokers, 15:12-18
BLOOD COAGULATION
effect of tobacco proteins, 4:60
smokers vs. nonsmokers, 12:84-85
smoking and thrombosis and, 4:59
BLOOD GLUCOSE
levels in smokers vs. nonsmokers,
12:84
BLOOD LIPIDS
effect of tobacco smoke and constitu-
ents on levels in animals, 4:61
levels in smokers vs. nonsmokers,
12:65
levels in smokers vs. nonsmokers vs.
ex-smokers, 12:83-84
BLOOD PLATELETS
effect of smoking, 12:84-85
BLOOD PRESSURE
(See also HYPERTENSION)
effect of cigar smoking, 13:34
effect of cigarette smoke vs. nico-
tine, 14:87
effect of involuntary smoking in
children, 11:27
effect of nicotine, 4:58, 14:79
effect of nicotine and oxprenolol,
12:54
effect of nicotine and propranolol,
12:53
effect of nicotine vs. cotinine, 14:91
effect of pipe smoking, 13:34
effect of propranolol in smokers,
12:37
effect of smoke inhalation in cats,
14:77
effect of smoking, 12:15-16
effect of smoking in enclosed spaces,
11:27
ex-smokers, 4:57
smokers vs. nonsmokers, 4:57
BLOOD PROTEINS
levels in smokers vs. nonsmokers,
12:84
BODY HEIGHT
» children, effect of maternal smoking,
8:21-23
infants, effect of maternal smoking,
8:19-21
BODY WEIGHT
(See also OBESITY)
blood pressure in smokers vs. ex-
smokers and, 4:57
children, effect of maternal smoking,
8:21-23
effect of cessation of smoking, 15:21
effect of smoking during pregnancy,
8:24
effect of tobacco smoke in pregnant
animals, 8:53
BORON TRIFLUORIDE
smoking and occupational exposure,
LT
BOSTON COLLABORATIVE DRUG
SURVEILLANCE PROGRAM
clinical drug effects in smokers vs.
nonsmokers, 12:35-37
BRAIN
effect of nicotine, 15:8
BREAST FEEDING
(See also LACTATION)
maternal smoking and, 8:51
maternal smoking and, research
needs, 8:78-79
in smokers vs. nonsmokers, 8:48
tobacco factory workers and, 8:48
BREATH
carbon monoxide content as measure
of tobacco usage, 15:30
BRITISH PERINATAL MORTALITY
STUDY 8-29, 8:42
Bronchial clearance
See TRACHEOBRONCHIAL
CLEARANCE
BRONCHIAL NEOPLASMS
(See also LUNG NEOPLASMS)
pipe smoking in etiology of, 13:28-29
BRONCHITIS
(See also BRONCHOPULMONARY
DISEASES; CHRONIC OBSTRUC-
TIVE LUNG DISEASE; OB-
STRUCTIVE AIRWAY DISEASES)
in coal miners , 13:35
effect of smoking on mortality, 2:41
mortality in cigar vs. cigarette vs.
pipe smokers, 13:34-35
prevalence in the United States, 6:19
small airways function and, 6:18
in smokers vs. nonsmokers, 6:39
smoking and, summary of findings,
1:18
smoking in etiology of, 3:5

smoking in gold miners and, 7:15
BRONCHOPULMONARY DISEASES
(See also BRONCHITIS; CHRONIC
OBSTRUCTIVE LUNG DISEASE;
OBSTRUCTIVE AIRWAY DIS-
EASES)
air pollution and occupational expo-
sure and, 1:19
antitrypsin deficiency and, 1:19
cigar and pipe smoking and, summa-
ry of findings, 1:28
heredity and, 1:19
smoking and, summary of findings,
1:18--19
BUSES
effect of involuntary smoking on
nonsmokers, 11:26
BUSINESSMEN
cessation of smoking, 22:19
BYSSINOSIS
(See also OCCUPATIONAL DIS-
EASES)
smoking in cotton workers and, 7:9

CADMIUM
(See also METALS)
content in mainstream cigarette
smoke, 14:60
levels in smokers vs. nonsmokers,
12:73
occupational hazards, 7:15
CAFFEINE
consumption and cessation of smok-
ing, 18:20
consumption and smoking as factors
in heart disease, 18:14
consumption in smokers vs. nonsmok-
ers, 18:13, 18:15
effect of aromatic hydrocarbons on
pharmacokinetics in rats, 12:32-
33
effect of benzo(a)pyrene on clearance
in rats, 12:32-33
CALCIUM
(See also METALS)
blood levels in smokers vs. nonsmok-
ers, 12:84
CANADIAN HOSPITAL ASSOCIA-
TION
hospital smoking policy recommenda-
tions, 22:20
CANADIAN PUBLIC HEALTH ASSO-
CIATION
members’ smoking attitudes, 22:7,
22:15
Cancer
See NEOPLASMS
CANNABIS
(See also DRUG ABUSE; MARI-
JUANA )
effect on enzyme activity in animals
and man, 12:42-43
CARBARYL
smoking and occupational exposure,
V7
CARBOHYDRATES
effect of smoking on metabolism,
12:65
CARBON DIOXIDE
assimilation, and tobacco leaf quality,
14:15
cardiovascular diseases and, 4:62
CARBON DISULFIDE
cardiovascular diseases and, 4:62
CARBON MONOXIDE
absorption, 14:98
animal model for hyperkinesis, 8:65
in aortic aneurysm etiology, 4:56
atherosclerosis and, 4:18
calculation of buildup in enclosed
spaces, 11:22
effect of low level exposure on angi-
na pectoris patients, 11:30, 11:34
effect of low level exposure on
chronic obstructive lung disease
patients, 11:31
effect of low level exposure on coro-
nary patients, 11:30
effect of maternal exposure on fetal
growth in rats, 8:60
effect on arteries in animals, 4:56
effect on blood cholesterol levels in
animals, 4:17, 4:61
effect on carboxyhemoglobin levels
in dogs and monkeys, 14:80
effect on cardiovascular system in
guinea pigs, 14:79
effect on cardiovascular system in
monkeys, 14:80
effect on cerebrovascular circulation,
4:50
effect on exercise induced angina
pectoris, 4:47

effect on fertility and pregnancy
outcome in rats, 8:60

effect on fetal growth in animals,
8:52

effect on fetus, research needs, 8:80

effect on heart in monkeys with
myocardial infarction, 4:40

effect on hemoglobin levels and red
cell mass, 12:82-88

effect on intermittent claudication,
4:54

effect on ischemia, 4:39

effect on lung function and cardio-
vascular system, 11:27-8

effect on maternal and fetal carbox-
yhemoglobin levels, 8:71-72

effect on maternal and fetal oxygen
tension, 8:61, 8:72

effect on maternal and fetal oxy-
hemoglobin saturation curves,
8:62, 8:72

effect. on mother and fetus after
maternal exposure in monkeys,
8:65

effect on newborn animals, 8:65

effect on pregnant mother and fetus
in animals, 8:57

effect on psychomotor performance,
11:28, 11:34

effect on tissue oxygenation, 8:61

effect on smoking habit, 15:6

hypoxia of sheep fetus and, 8:63-65

in maintenance of smoking habit,
15:15

maternal-fetal exchange in sheep,
8:59

maternal-fetal exchange in sheep
and dogs, 8:58

metabolism in maintenance of smok-
ing habit, 15:17

monitoring in cessation studies, 19:7,
19:20

myocardial infarct and, 4:20

occupational hazards, 7:8

reduction methods, 14:114

smoke dosimetry and, 14:75

smoking and ambient air quality
standard, 11:21

in sudden cardiac death induction in
cholesterol-fed monkeys, 4:45
CARBON MONOXIDE LEVELS

(See also CARBOXYHEMOGLOBIN
LEVELS)
in breath, and carboxyhemoglobin
levels in blood, 15:30
in cigar smoke, 14:38
in cigar vs. cigarette smoke, 12:12
in cigar vs. pipe smoke, 14:104
in cigarette smoke, 14:38
effect of filters, 14:105
effect of smoking in airplanes and
buses, 11:26
effect of smoking in enclosed spaces,
11:15, 11:33-34
in main- and sidestream smoke, 11:15
reduction in cigarette smoke, 14:104
in tobacco smoke, and health charac-
teristics, 3:11
in various tobacco products, 11:15

CARBOXYHEMOGLOBIN LEVELS

(See also CARBON MONOXIDE
LEVELS)

angina pectoris, intermittent claudi-
cation and myocardial infarction
and, 4:54

carbon monoxide occupational expo-
sure in smokers vs. nonsmokers
and, 7:8

cigarette smoke inhalation and, 2:21

in determination of inhalation levels
in cigar and pipe smokers, 13:18

effect of carbon monoxide in dogs
and monkeys, 14:80

effect of involuntary smoking, 11:21,
11:28

effect on driving ability, 11:28-29

effect on fetal blood flow, 8:72-73

effect on fetal mortality in sheep,
8:62-63

effect on maternal and fetal oxygen
tension, 8:61-64, 8:72-73

as indicator of carbon monoxide in
blood, 3:12

in infants of smokers vs. nonsmok-
ers, 8:69

maternal, effect of smoke inhalation
in pregnant sheep, 8:53

maternal, effect on placental oxygen
consumption, 8:68-69

maternal and fetal, effect of carbon
monoxide, 8:70-72

maternal and fetal, effect of mater-
nal smoking, 8:70

maternal and fetal, in monkeys, 8:65

maternal and fetal, in nonsmokers,
8:70

maternal and fetal, in rabbits, 8:60

maternal and fetal, in sheep, 8:58-59,
8:61

maternal and fetal, oxyhemoglobin
saturation curves and, 8:62-63

in measuring tobacco usage, 15:29

in methylene chloride workers, 7:8-9

monitoring in smoking cessation, 19:7

in nonsmokers, 11:23

in nonsmoking blood donors, 11:23

as smoke inhalation indicator, 14:75

CARBOXYLIC ACIDS

levels in tobacco varieties, 14:57

CARCINOEMBRYONIC ANTIGEN

in colonic neoplasm diagnosis, 12:59-
62

levels in smokers vs. nonsmokers,
12:61-62

levels in smokers vs. nonsmokers vs.
ex-smokers, 12:86

in lung neoplasm diagnosis, 12:61

CARCINOGENESIS

(See also NEOPLASMS)

catechols and, 14:106

cigarette tar and beta radiation in
mice, 7:10

effect of polyaromatic hycrocarbon
reduction, 14:109

interaction of carcinogens, cocarcino-
gens and tumor promoters, 5:54-
55

isoprenoids in, 14:49

mechanisms, 5:53-58

multi-stage model, 5:58

polynuclear aromatic hydrocarbons in,
14:51-52

role of enzyme activity, 5:55, 57

tobacco in animals, 5:53-54

tobacco in animals, summary of
methods, 5:54-55

tobacco tars in animals, 13:31-32

CARCINOGENS

(See also COCARCINOGENS; TU-
MOR PROMOTERS)
cigar and pipe tobacco condensates,
1:28
in cigar vs. cigarette vs. pipe tars,
13:30-32
cigarette smoke constituents, 1:30
metals in tobacco, 14:59-60
in tobacco smoke gas phase, 5:54-55

tobacco smoke PAH structural for-
mulae, 14:53

in tobacco smoke particulate phase,
5:54-56, 14:65

CARDIOVASCULAR CURRICULUM

EDUCATION PROJECT
programmed instruction, 23:19, 23:21-
22

CARDIOVASCULAR DISEASES

(See also CORONARY HEART
DISEASE; CEREBROVASCULAR
DISEASES; ISCHEMIA; MYO-
CARDIAL INFARCT)
atherosclerosis in etiology of, 4:8
cessation of smoking as preventive
medicine, 4:66
cessation of smoking in patients,
22:18, 22:17
cigar and pipe smoking and, summa-
ry of findings, 1:28
cigar smoking in etiology of, 13:32~
34
effect of involuntary smoking, 11:29-
30
effect of oral contraceptives and
smoking on risk, 4:60-61
effect of smoking on mortality ratio,
2:39
mortality in cigar vs. cigarette vs.
pipe smokers, 13:33-34
mortality ratio in smokers vs. non-
smokers in Japan, 4:21, 4:34-35
nicotine and, 14:79
pipe smoking in etiology of, 13:32-34
research needs, 4:64-66
smoking and, summary of findings,
1:13-15
smoking and carbon monoxide occu-
pational exposure and, 7:8
sudden cardiac death, 4:42-43
tobacco smoke constituents and,
4:62-63

CARDIOVASCULAR SYSTEM

(See also ARTERIES; ARTERI-

OLES; HEART)

allergic response to tobacco, 10:22-23

effect of carbon monoxide exposure,
11:27-28

effect of carbon monoxide in guinea
pigs, 14:79

effect of carbon monoxide in mon-
keys, 14:80

effect of cessation of smoking,
15:20-21, 15:28
effect of nicotine, 12:52-54, 14:89
effect of nicotine in animals with
coronary heart disease, 4:40
effect of nicotine or tobacco smoke
in animals with myocardial in-
farct, 4:45
effect of propranolol and nicotine,
12:53
effect of propranolol in smokers,
12:37
effect of rapid smoking, 19-25-26
effect of smoke inhalation, 14:74-75
effect of smoking, 15:12-13, 15:19
maternal and fetal, effect of nicotine
injection in animals, 8:55-56
CASING MATERIALS
effect on smoke constituents, 14-28
CATECHOLAMINES
effect of nicotine in rats, 14:88
effect of nicotine on levels, 14:78,
14:89
effect of smoking on plasma levels,
14:88
fatty acids and, 14:90
hyperglycemia and, 14:90
smoking habit and, 15:8
CATECHOLS
in mainstream cigarette smoke, 14:54
reduction in gas phase cigarette
smoke, 14:106
in sidestream cigarette smoke, 14:54
structural formulae, 14:56
CENTRAL NERVOUS SYSTEM
effect of carbon monoxide and nico-
tine on blood circulation, 4:50
effect of cessation of smoking, 15:21
effect of cigarette smoke, 15:11
effect of nicotine, 14:89
effect of smoking, 15:18-19
fetal and neonatal, effect of mater-
nal nicotine injection in animals,
8:56-57
CEREBROVASCULAR DISEASES
(See also CARDIOVASCULAR DIS-
EASES)
animal models, 4:49-50
cigar smoking in etiology of, 13:32-
33
clinical diagnostic classification, 4:49
effect of smoking on risk, 4:50-52

mortality rates and ratios in male
vs. female smokers vs. nonsmok-
ers, 4:51

pipe smoking in etiology of, 13:32-38

research needs, 4:52

risk factors, 4:49

smoking and, summary of findings,
1:14-15

smoking in etiology of, 4:50

CESSATION OF SMOKING

(See also ANTISMOKING CAM-
PAIGNS; PREVENTION OF
SMOKING; WITHDRAWAL CLIN-
ICS)
adult programs, 21:14-15, 21:22-26
age groups and sex ratio and, 3:18
antismoking campaigns and, 19:9-10
behavioral interventions, 16:14-18,
19:19-29
businessmen, 22:19
cardiovascular diseases and, summary
of findings, 1:14-15
college students, 22:18
coronary heart disease prevention
programs, 19:14-16, 19:34, 21:24-
25
counseling, 19:12-14
degree of deprivation and, 15:27
drug therapy, 19:16-17
early behavioral effects, 15:22
early physiological effects, 15:20-22
effect on bladder neoplasm risk, 5:45
effect on blood chemical analysis,
12:87
effect on blood circulation, 4:54
effect on calcium and iodine levels
in blood, 12:84
effect on carcinoembryonic antigen
levels, 12:86
effect on coronary heart disease
morbidity and mortality ratios,
4:28-31, 4:34-35, 4-38
effect on enzyme activity, 12:41
effect on laryngeal neoplasm risk,
5:34, 5:37-38
effect on lung function, 6:22-23
effect on lung neoplasm risk and
mortality ratio, 5:24-26
effect on morbidity, summary of
findings, 1:12-13

effect on mortality, 2:26-30

effect on mortality ratio, summary
of findings, 1:11

evaluation of programs, 1:32-33

hypnosis, 19:17-18

laryngeal neoplasms and, summary
of findings, 1:16-17

long term physiological effects,
15:22-24

lung neoplasms and, summary of
findings, 1:16

medical students, 22:18

methods, 19:16-380

motivation, 18:19-20

myocardial infarct patients, 19:14

nicotine pharmacology and, 14:94,
14:97

obesity and, 12:67

patients with respiratory or cardio-
vascular diseases, 22:18

personality and, 18:17-18, 18:21-22

personality of smokers vs. nonsmok-
ers, vs. ex-smokers and, 15:24

physician’s advice and, 3:15-18, 21:11

pregnant women, 22:16, 22:18, 22:23

as preventive medicine for cardiovas-
cular diseases, 4:66

program in Sweden, 19:15

recidvism, 15:22-23

research design, 16:17, 19:5-9, 19:32-
36

self-motivated, 19:33, 19:35, 21:15

smoker’s reporting and, 15:31

Smoking Withdrawal Study Center
(Toronto), 19:11

tobacco withdrawal syndrome time
course, 15:26

and weight gain, 19:31

withdrawal clinics in Great Britain,
19:15

Chewing gum

See NICOTINE CHEWING GUM;
ANTITOBACCO CHEWING GUM

CHILDREN

(See also INFANTS)

attitudes toward smoking, 17:5-6

effect of involuntary smoking on al-
lergies, 10:14

effect of involuntary smoking on
heart rate and blood pressure,
11:27

effect of maternal smoking during
pregnancy, 8:21-23
effect of parental smoking, 11:31
effect of parental smoking on respi-
ratory disease prevalence, 11:32,
11:34
Health Activities Project, 21:20
smoking and respiratory tract dis-
eases, 6:11
CHLORINE
occupational hazards, 7:10
CHLOROMETHYL ETHERS
occupational hazards, 7:15-16
and smoking in lung neoplasm etiolo-
gy, 5:29
Cholesterol
See BLOOD CHOLESTEROL LEV.
ELS
CHRONIC OBSTRUCTIVE LUNG DIS-
EASE
(See also BRONCHITIS; BRON-
CHOPULMONARY DISEASES;
EMPHYSEMA; OBSTRUCTIVE
AIRWAY DISEASES; RESPIRA-
TORY TRACT DISEASES)
air pollution and, 6:36
cigar smoking in etiology of, 13:34-
38
effect of low level carbon monoxide
exposure, 11:31
effect of smoking on mortality, 2:41
mortality, 6:10
mortality in cigar vs. cigarette vs.
pipe smokers, 13:34-35
nitrogen oxide absorption and, 14:99
pipe smoking in etiology of, 13:34-38
smal] airways function and, 6:11~12
small airways function and respira-
tory symptoms and, 6:13, 6:18
smoking and air pollution and, 6:37
smoking and antitrypsin deficiency
and, 6:34
smoking and heredity and, 6:35-36
smoking and occupational exposure
to dust and, 6:36
smoking and socioeconomic status
and, 6:38

smoking as risk factor, research rec-
ommendations, 6:41-42
smoking history and, 6:10
Chronic obstructive pulmonary disease
See CHRONIC OBSTRUCTIVE
LUNG DISEASE
Cigar smoke
See SMOKE, CIGAR
CIGARETTE CONSUMPTION
(See also SMOKING LEVELS)
annual per capita, United States
1925-1950, A:5
annual per capita, United States
1950-1978, A:5
annual per capita, United States
1963-1977, A:7
changes from 1968-1977, A:6
effect of composition, A:18-19
FTC, DOA, and Maxwell Report sta-
tistics, A:6
historical trends in the United
States, 1:5
increase in adults over time, A:17
low-tar brands, A:20-21
reasons for increase, A:17
in the United States, A:22-23, 14:13
CIGARETTE MANUFACTURING
effect on carcinogenicity, 14:29-30
effect on cigarette smoke constitu-
ents, 14:28-30
levels in the United States, 14:11
role in smoke constituent delivery,
14:9
tobacco types in the United States
and, 14:13
CIGARETTE PAPER
effect on carbon monoxide levels,
14:104
effect on smoke constituents, 14:29
effect on temperature profile, 14:35
Cigarette smoke
See SMOKE, CIGARETTE
Cigarette smoke, gas phase
See GAS PHASE, CIGARETTE
SMOKE
Cigarette smoke, particulate phase
See PARTICULATE PHASE, CIG-
ARETTE SMOKE; TARS, CIGA-
RETTE
Cigarette smoking
See SMOKING
Cigarette tars
See TARS, CIGARETTE
CIGARETTES
(See also SMOKE, CIGARETTE;
SMOKERS; SMOKING, CIGA-
RETTE; TOBACCO, CIGARETTE)
effect of design on ciliatoxicity,
14:105
effect of nicotine and tar content on
mortality, 2:22
effect of static burning temperature
on smoke formation, 14:36
experimental, carcinogenicity, 14:29-
30
manufacturing levels, 14:11
nicotine reduction, 14:44
phenol levels in filtered vs. nonfil-
tered, 14:57
pyrolysis reactions, 14:9
sales weighted average tar content
1954-1977, A:19
tar reduction, 14:43
temperature profiles, 14:35-36
United States Government definition,
13:10
CIGARETTES, FILTER
consumption patterns, A:23
increase in consumption, A:19
CIGARETTES, HIGH-NICOTINE
anxiety levels and, 16:7-8
effect on self-regulation of smoking,
16:19
CIGARETTES, LESS HAZARDOUS
effect on coronary heart disease
mortality rates, 4:38
effect on laryngeal neoplasm risk,
5:34-36
effect on lung neoplasm mortality
ratio, 5:15-17
effect on lung neoplasm risk, 5:16,
5:18-19
effect on mortality ratio, 1:11

effect on mortality ratio in males vs.

females, 2:23-25
isoprenoids and, 14:49

nicotine reduction and, 14:108
research and development, 1:31
research recommendations, 14:120
tar reduction and, 14:108
CIGARETTES, LOW-NICOTINE
anxiety levels and, 16:7-8
consumption trends, 16:16-17, 19:29
degree of deprivation and, 15:27
dependence and, 14:98
effect on mortality ratio, 2:23
effect on self-regulation of smoking,
16:19
promotion in hospital setting, 22:22
smoker preference, 15:8
CIGARETTES, LOW-TAR
(See also CIGARETTES, LESS
HAZARDOUS)
consumption patterns, A:20-21
market share 1967-1978, A:20-21
trends in tar and nicotine content,
A:23-24
CIGARETTES, NON-NICOTINE
as reinforcers, 16:8-9
CIGARETTES, NONTOBACCO
effect on ciliary activity in proto-
zoans, 6:32
patellar reflexes and, 14:92
CIGARS
(See also SMOKE, CIGAR; SMOK-
ERS, CIGAR; SMOKING, CIGAR;
TOBACCO, CIGAR)
consumption in the United States,
14:18
effect of manufacturing process,
14:30
smoking characteristics of ex-ciga-
rette smokers, 19:29
tar levels, 14:44
United States Government definitio
13:10
CIGARS, LITTLE
effect of filters on nitrogen oxide
content, 14:39
nicotine levels, 14:44, 14:87
tar levels, 14:44
CILIARY ACTIVITY
(See also MUCOCILIARY
SYSTEM)
effect of cigarette smoke, 6:32
effect of phenol, 14:81
effect of smoke from nontobacco cig-
arettes in protozoans, 6:33

effect of smoking, 10:14-15

effect of tobacco smoke, 6:32

gas phase cigarette smoke and,
14:105

CILIATOXICITY

agent reduction methods, 14:114

cigar smoke, 13:36-37

cigarette design and, 14:105

effect of carbon filters, 14:107

effect of charcoal filtration, 14:105

gas phase, cigarette smoke, 14:106

gas phase, tobacco smoke, 5:54-55

reduction in gas phase, cigarette
smoke, 14:104—105

COAL

dust, occupational hazards, 7:9

COCARCINOGENS :

(See also CARCINOGENS; TUMOR
PROMOTERS)
asbestos and cigarette smoke, 5:28
eatechols and cigarette smoke, 14:106
polynuclear aromatic hydrocarbons,
14:52
role in carcinogenesis, 5:54
in tobacco smoke particulate phase,
5:54-55
uranium and cigarette smoke, 5:28

Coffee :

See CAFFEINE

COLLABORATIVE PERINATAL

PROJECT OF THE NINCDS, 8:30,
8:45

COLONIC NEOPLASMS

carcinoembryonic antigen test in di- —
agnosis of, 12:59-62

COMMUNITY PROGRAMS

antismoking education, 23:14-15
D-day project (Monticello, Minneso-
ta), 21:25

CONGENITAL MALFORMATIONS

effect of carbon monoxide exposure
in pregnant rats, 8:60-61

effect of maternal’ nicotine injection
in mice, 8:54

CONTINGENCY CONTRACTING

aversive therapy and, 19:30

modification of smoking behavior,
19:21-22, 19:28-29

stimulus control treatment and, 16:16

CONTRACEPTIVES, ORAL

cardiovascular diseases and smoking
and, summary of findings, 1:14

effect on high density lipoprotein
levels, 4:62

interactive effect with smoking on
cardiovascular disease risk, 4:50,
4:60-61

interactive effect with smoking on
myocardial infarct risk, 4:35

interactive effect with smoking on
subarachnoid hemorrhage risk,
4:60-61 , ,

mortality risk compared with preg-
nancy and childbirth, 12:52

myocardial infarct and smoking and,
12:51-§2

stroke and smoking and, 12:51

thromboembolism and smoking and,
4:59, 12:51

COOPERATIVE EXTENSION SER-

VICE
dissemination of health information,
21:22

CORONARY HEART DISEASE

(See also ANGINA PECTORIS;
ATHEROSCLEROSIS; ISCHEMIA;
MYOCARDIAL INFARCT;
. SUDDEN CARDIAC DEATH;
THROMBOSIS)
aortic aneurysm and, 4:55
atherosclerosis in etiology of, 4:7
cigar smoking in etiology of, 13:32-.
33
effect of age, smoking duration and
smoking levels on annual proba-
bility of death, 4:35
effect of low level carbon monoxide
exposure, 11:30
effect of physical activity in smok-
ers, 4:38 -
heredity and, 4:66
high density lipoprotein levels and,
4:61-62 .
morbidity and mortality rates and
ratios in ex-smokers, 4:28-31,
4:34-35, 4-38
morbidity and mortality ratios in
smokers vs. nonsmokers, 4:22-23,
4:36-37
mortality ratio in smokers, 2:39
nicotine and, 14:89
pipe smoking in etiology of, 13:32-38
risk factors, 4:21, 4:36
smoking and, 4:21
smoking and hypertension and, 4:58
sudden cardiac death and, 4:41-43
CORONARY PREVENTION PRO-
GRAMS
effect on cessation of smoking,
19:14-16, 19:34, 21:24-25
North Karelia Project, 19:15
workplace detection program, 22:16—
17, 22:19
Cost
See ECONOMICS
COTININE
(See also ALKALOIDS, TOBACCO;
NICOTINE METABOLITES)
in amniotic fluid after maternal in-
jection in animals, 8:54
effect on blood pressure and heart
rate, 14:91
levels in measuring tobacco usage,
15:30
metabolism, 14:94
relative molar potency in cigarette
smoke, 14:96
as smoke inhalation indicator, 14:75
structural formula, 14:46
COTTON
dust, occupational hazards, 7:9
COUGH
effect of chloromethyl ether exposure
in smokers vs. nonsmokers, 7:16
Curing
See TOBACCO CURING
CYANIDES
(See also HYDROGEN CYANIDE;
THIOCYANATE LEVELS)
absorption, 14:99
in cigarette smoke, 14:39-40
effect on hemoglobin levels and red
cell mass, 12:83
Cyclopentanediones
See HETEROCYCLIC COM-
POUNDS
CYTOCHROME 65
role in drug metabolism, 12:11, 12:18
CYTOCHROME P-450
role in drug metabolism, 12:7-8,
12:10-20
spectral properties, 12:18-20
storage and activity sites, 12:16

CYTOCHROME P.-450
effect of aromatic hydrocarbons,
12:7-8
effect of aromatic hydrocarbons on
synthesis, 12:17-20
spectral properties, 12:18-20

D-DAY PROJECT (MONTICELLO,
MINNESOTA)
community cessation program, 21:25
DDT
in breast milk of smoking mothers,
8:51
as tobacco residue, 14:61
DENTISTS
antismoking advice to patients,
21:11-12, 22:16-17
smoking habits, 22:12-14
DEPENDENCE
effect of smoking characteristics,
14:97, 15:25
low-nicotine cigarettes and, 14:98
in maintenance of smoking habit,
15:17-18
nicotine and, 14:97
tobacco withdrawal syndrome and,
15:24-25
DEPRIVATION
effect of gradual reduction, 15:27
low-nicotine cigarettes and, 15:27
DERMATITIS, CONTACT
in tobacco workers, 10:23
DEXAMETHASONE
effect of smoking on corticosteroid
secretion, 12:37
DIABETES
peripheral vascular disease in smok-
ers vs. nonsmokers and, 4:53
DIBENZ(a, h)ANTHRACENE
structural formula, 14:53
DIENES
in cigarette smoke, 14:41
DIET
in atherosclerosis induction in ani-
mals, 4:9
pancreatic neoplasms and, 5:51
DIETHYLNITROSAMINE
(See also NITROSAMINE CON-
TENT; NITROSAMINES)
effect of smoking on levels in enc-
losed spaces, 11:25
in lung neoplasm induction in ham-
sters, 5:30
DINITRO-ORTHO-CREOSOL
smoking and occupational exposure,
7:7
DIURNAL VARIATIONS
in smoking habit, 15:25-26
DOSIMETRY
effect of carbon monoxide levels,
14:75
in smoke inhalation methodology,
14:74
DRIVING ABILITY
effect of alcoho! and carbon monox-
ide, 11:29
effect of carboxyhemoglobin levels,
11:28
DRUG ABUSE
(See also CANNABIS; MARIJUA-
NA)
attitudes and smoking habit, 18:10
smokers vs. nonsmokers, 18:13-15
smoking in youth and, 17:23
DRUG METABOLISM
(See also PHARMACODYNAMICS;
PHARMACOKINETICS )
effect of aromatic hydrocarbons,
12:7-9
effect of smoking, summary of find-
ings, 1:25-26
ethanol, in smokers vs. nonsmokers,
12:39
mechanisms of enzyme induction,
12:20-22
role of aryl hydrocarbon hydroxylase,
12:7-9
role of cytochrome bs, 12:11, 12:13
role of cytochrome P-450, 12:7-8,
12:10-20
role of microsomal electron transport
system, 12:10-15
role of microsomal mixed function
oxidase systems, 12:10-22
role of NADPH reductase, 12:10-15
warfarin, effect of smoking, 12:55
DRUG THERAPY
smoking cessation and, 19:16-17
Duodenal ulcer
See ULCER, PEPTIC
DUODENOGASTRIC REFLUX
effect of smoking, 9:16
DUST
coal, obstructive airway diseases and,
7:9
cotton, byssinosis and, 7:9

cotton, “Monday morning fever” and,
7:9

cotton, obstructive airway diseases
and, 7:9-10

gold, chronic bronchitis and, 7:15

rubber, occupational hazards, 7:13

ECONOMICS
cigarette cost and cessation, 18:19
cigarette cost and consumption,
18:23-24
cigarette tax revenues, 21:18
EMPHYSEMA
(See also BRONCHOPULMONARY
DISEASES; CHRONIC OBSTRUC-
TIVE LUNG DISEASE)
antitrypsin deficiency in etiology of,
6:33-34
in coal] miners , 13:35
effect of smoking on mortality, 2:41
enzyme induction and, 6:28
mortality in cigar vs. cigarette vs.
pipe smokers, 3:34-35
prevalence in the United States, 6:20
small airways function and, 6:18
smoking and, 6:25
smoking and, summary of findings,
1:18-19
smoking in etiology of, 3:5
smoking in uranium miners and, 7:14
smoking levels and lung pathology,
6:24
Employee programs
See WORKPLACE PROGRAMS
ENVIRONMENT
effect on mortality, 2:42
ENZYME ACTIVITY
(See also ARYL HYDROCARBON
HYDROXYLASE)
in cotinine metabolism, 14:94
effect of aromatic hydrocarbons,
12:7-9
effect of cessation of smoking, 12:41
effect of cigarette smoke conden-
sates, 6:29
effect of cigarette smoke constitu-
ents, 12:7
effect of marijuana, 12:42-43
effect of methylcholanthrene, 12:21-
22
effect of nicotine, 12:27-28, 14:87
effect of nicotine in rat intestines,
12:76
effect of nitric oxide in rats, 14:81
effect of smoke inhalation in dogs,
14:78
effect of smoking, 1:25-26, 5:57,
12:8-9
effect of tobacco smoke, 10:16,
12:27-28, 12:75-76
in emphysema etiology, 6:28
mechanism of induction in drug me-
tabolism, 12:20-22
nicotine metabolism and, 14:87
role in carcinogenesis, 5:55, 5:57
role of RNA and protein synthesis,
12:21-22
ENZYMES
(See also ARYL HYDROCARBON
HYDROXYLASE)
alkaline phosphatase, 12:76
aminoazo dye N-demethylase, 12:9
guanylate cyclase, 14:80-81
role of microsomal mixed function
oxidase systems in drug metabo-
lism, 12:10-22, 12-76
role of NADPH reductase in drug
metabolism, 12:10-15
serum glutamic oxalacetic transami-
nase, 12:84
EPIDEMIOLOGY
American Cancer Society 9-State
Study, 2:15
American Cancer Society 25-State
Study, 2:12, 2:14
British Doctors Study, 2:12
California men in various occupa-
tions, 2:15
Canada Veterans Study, 2:14-15
Japanese Study, 2:14
smoking related mortality studies,
2:13
Swedish Study, 2:15
United States Veterans Study, 2:14
ERYTHROCYTES
smokers vs. nonsmokers, 12:82-83
ESOPHAGEAL NEOPLASMS
alechol consumption and smoking in
etiology of, 5:43-44, 13:25-26
animal models, 5:44
induced by benzo(a)pyrene and etha-
nol in animals, 5:44
induced by nitrosamines in animals,
5:44
mortality in cigar vs. cigarette vs.
pipe smokers, 13:24-25

mortality ratio in cigar and pipe
smokers, 5:43
mortality ratio in smokers, 5:42-43
relative risk ratio in cigar vs. ciga-
rette vs. pipe smokers, 13:26
smoking and, summary of findings,
1:17
ESOPHAGUS
effect of smoking, 5:44
effect of smoking and alcohol con-
sumption, 13:25-26
ESTROGENS
effect on heart attack risk in males,
4:61
myocardial infarct and smoking and,
12:52
Ethanol
See ALCOHOL
EX-SMOKERS
absenteeism, 3:8, 3:13
activity limitation, 3:14
annual probability of dying, 2:30-34
bladder neoplasm risk, 5:46
blood chemical analysis, 12:87
blood circulation, 4:54
blood lipid levels, 12:83
blood pressure, 4:57
calcium and iodine levels in blood,
12:34
carcinoembryonic antigen levels,
12:86
chronic obstructive lung disease and
mortality, 6:10-11
coronary heart disease morbidity and
mortality rates and ratios, 4:28-
31, 4:34-35, 4-38
effect of smoking duration and
smoking levels on mortality ratio,
2:28-29
heart conditions, 3:16-17, 3:19
hospitalization, 3:14~16
laryngeal neoplasm risk, 5:34, 5:37-38
leukocyte count, 12:81
lung function, 6:23
lung function and sex ratio, 6:23
lung neoplasm mortality ratio, 5:24—
26
mortality, 2:26-30
mortality and years since quitting,
2:27-30, 2:25
mortality in cigar and pipe smokers,
13:8
mortality ratio and reasons for quit-
ting, 2:27-29
myocardial infarct, 4:21
perception of health status, 3:14-15
personality and cessation of smoking
15-24
physician visits, 3:15, 3:17
respiratory tract diseases in young
adults, 6:12
small airways function, 6:14-16
smoking levels and lung pathology,
6:24, 6:27
EXCESS DEATHS
(See also MORTALITY)
age groups in the United States,
2:11
definition, 2:11
EXERCISE
(See also PHYSICAL ACTIVITY)
effect of smoke inhalation in dogs,
14:77-78
effect of smoke inhalation in rats,
14:77
EXTRAVERSION
cessation of smoking and, 18:17-18
maintenance of smoking and, 18:5-7
EYE IRRITATION
effect of smoking in enclosed spaces,
11:26
effect of tobacco smoke, 10:21
effect of ventilation rate, 11:26-27

FATTY ACIDS
catecholamines and, 14:90
effect of nicotine, 14:90
effect of nicotine on levels in blood,
12:40
levels in cigarette smoke, 14:58
FEDERAL CIGARETTE LABELLING
AND ADVERTISING ACT, A:7
FEDERAL COMMUNICATIONS COM-
MISSION
Fairness Doctrine, 18:23
FEDERAL TRADE COMMISSION
cigarette tar content and, 14:44
Females
See WOMEN
Feminism
See WOMEN’S MOVEMENT
FETAL GROWTH
(See also BIRTH WEIGHT)
effect of maternal exposure to car-
bon monoxide, 8:60

effect of maternal smoking, 8:12,
8:17-19, 8:21
effect of maternal smoking, summa-
ry of findings, 1:21
effect. of maternal smoking in ani-
mals, research needs, 8:78
effect of tobacco smoke in animals,
8:52
maternal smoking and maternal
weight gain and, 8:24-25
FETAL MORTALITY
(See also MORTALITY; NEONA-
TAL MORTALITY; PERINATAL
MORTALITY)
carboxyhemoglobin levels in sheep
and, 8:62
effect of maternal smoking and ges-
tational age, 8:43
effect of maternal smoking and oth-
er factors, 8:41
research needs, 8:75
smoking, abruptio placentae, placenta
previa and bleeding in pregnancy
and, 8:40
FETUS
(See also PLACENTA; PREGNAN-
CY; PRETERM DELIVERY)
effect of maternal smoking, 8:67-68
effect of oxygen availability, 8:17
FIBER OPTICS
in tobacco analysis, 14:9
FIBROSIS
smoking in asbestos workers and,
7:12
smoking levels and asbestos expo-
sure, 7:13
Filter cigarettes
See CIGARETTES, FILTER
FILTERS .
effect on carbon dioxide content,
14:38, 14:104-105
effect on catechol content in gas
phase cigarette smoke, 14:106
effect on ciliatoxic agent content,
14:105, 14:107
effect on cyanide content, 14:40
effect on laryngeal neoplasm risk,
5:34-36
effect on lung neoplasm risk, 5:16,
5:18-19
effect on nitrogen oxide content,
14:39
effect on nitrosamine content, 14:39
effect on nitrosamine content in gas
phase cigarette smoke, 14:107
effect on phenol content, 14:54,
14:57, 14:106
effect on polonium-210 content,
14:113
effect on smoke constituents, 14:29
effect on tar delivery, 14:44
effect on temperature profile, 14:35
summary of research and develop-
ment, 1:31
FLAVORINGS
in cigarette manufacturing, effect on
smoke constituents, 14:28-19
FLUORIDES, INORGANIC
smoking and occupational exposure,
viv)
FLUOROCARBON POLYMERS
smoking and polymer fume fever,
7:6
FORMALDEHYDE
smoking and occupational exposure,
V7
4-H Programs
See COOPERATIVE EXTENSION
SERVICE
FRAMINGHAM HEART STUDY
angina pectoris, 4:46
high density lipoprotein levels in
smokers vs. nonsmokers, 4:61-62
peripheral vascular disease, 4:53
sudden cardiac death, 4:48
FUROSEMIDE
effect of smoking on diuretic action,
12:37, 12:54
FUTURE SMOKERS
maternal, and infant birth weight,
8:26-27
maternal, and personality characteris-
tics, 8:26

GAS PHASE, CIGARETTE SMOKE
chemical composition, 14:38
ciliatoxie agent levels, 14:106
constituent levels, 15:6—7
constituents in main- vs. sidestream

smoke, 11:6
definition, 14:35
effect of filters on ciliatoxicity,
14:107
reduction of carbon monoxide, 14:104
reduction of catechols, 14:106

reduction of ciliatoxic agents, 14:105
reduction of phenols, 14:106
reduction of nitrosamines, 14:107
reduction of toxicity, 14:104
toxie agent levels, 14:44
toxicity reduction methods, 14:114
GASTRIC SECRETION
effect of nicotine, 9:18-14
effect of nicotine in cats, 9:12-13
effect of smoking in peptic ulcer pa-
tients and the normal population,
9:13
Gastric ulcer
See ULCER, PEPTIC
GASTRITIS
smoking in etiology of, 9:16
GEORGIA HEART ASSOCIATION
hypertension education program,
21:21
GESTATION
effect of maternal nicotine injection
in rats, 8:54
smoking and duration of, 8:18
GESTATIONAL AGE
effect of maternal smoking levels on
birthweight, 8:20
maternal smoking and birthweight,
8:19
maternal smoking and risk for
abruptio placentae, placenta pre-
via, and premature membrane
rupture, 8:44, 8:46
maternal smoking and risk for pre-
term delivery, 8:44
GLUTETHIMIDE
pharmacokinetics in smokers vs. non-
smokers, 12:33
GLYCERIN
levels in cigarettes, 14:63
GLYCOLS
levels in cigarettes, 14:63
GOLD
dust, occupational hazards, 7:15
GROUP PROGRAMS
American Cancer Society, 19:10
5-Day Pian, 19:10, 21:15-16
hypnosis and, 19:17-18
SmokEnders, 19:11, 21:16
Smoking Withdrawal Study Centre,
19:11
HABITUATION
opponent process model, 16:9-11,
16-14-15
HEALTH ACTIVITIES PROJECT
health education for children, 21:20
HEALTH AND NUTRITION EXAMI-
NATION SURVEY, 3:11-12, 3:17
HEALTH EDUCATION
(See also SCHOOL PROGRAMS;
ADULT EDUCATION)
evaluation of School Health Curricu-
lum Project, 20:21
information dissemination, 23:27-28
nonschool antismoking programs for
youth, 20:22-24
role of health professionals, 22:14-19
role of schools, 17:15
Saskatoon Smoking Study, 20:11-12,
23:25
summary of methodologies and pro-
grams, 1:33-34
teacher certification requirements,
23:28-31
Teenage Self Test, 20:22
HEALTH INTERVIEW SURVEY, 3:3-
18
smoking prevalence data, A:13
smoking prevalence in white and
black adults 1965-1976, A:15
HEALTH PROFESSIONALS
(See also PHYSICIANS; NURSES;
PHARMACISTS; DENTISTS)
cessation of smoking advice, 19:13-
14, 21:11-12
as health educators, 22:5-6, 22:14-19
as role models, 22:6-9
smoking habits, 22:9-14, 22:23
HEART
(See also CARDIOVASCULAR
SYSTEM; HEART RATE; MYO-
CARDIUM)
conditions, in smokers vs. nonsmokers
vs. ex-smokers, 3:16-17, 3:19
effect of nicotine, 14:78
effect of smoke inhalation and exer-
cise in dogs, 14:78
effect of smoke inhalation in cats,
14:77
function, in animals with coronary
heart disease, 4:40

Heart disease
See CARDIOVASCULAR DIS-
EASES; CORONARY HEART DIS-
EASE
HEART RATE
effect of involuntary smoking in
children, 11:27
effect of nicotine, 4:58
effect of nicotine vs. cotinine, 14:91
effect of smoking, 12:15-16
fetal, effect of maternal smoking,
8:10, 8:67
sudden cardiac death and ventricular
fibrillation, 4:43
sudden cardiac death and ventricular
premature beats, 4:42
HEMATOCRIT
infants of smokers vs. nonsmokers,
8:69
smokers vs. nonsmokers, 12:82-83
HEMODYNAMICS
(See also BLOOD CIRCULATION)
effect of smoke inhalation in dogs,
14:76
HEMOGLOBIN LEVELS
(See also CARBON MONOXIDE;
CARBOXYHEMOGLOBIN LEV-
ELS; ERYTHROCYTES)
effect of carbon monoxide, 12:82-83
effect of cyanide, 12:88
smokers vs. nonsmokers, 12:82-83
HEREDITY
atherosclerosis in animals and, 4:9
bronchopulmonary diseases and, 1:19
coronary heart disease and, 4:66
in establishing smoking habit, 15:9-
10
lung neoplasms and, 5:23
smoking and chronic obstructive lung
disease risk, 6:35-36
smoking related mortality and, 2:41-
42
HETEROCYCLIC COMPOUNDS
(See also AROMATIC AMINES)
in cigarette smoke, 14:52, 14:57
structural formulae of tobacco smoke
carcinogens, 14:55
weakly acidic, structural formulae,
14:56
HIGH DENSITY LIPOPROTEINS
coronary heart disease and, 4:61-62
effect of oral contraceptives on lev-
els, 4:62
effect of smoking on levels in males
vs. females, 4:61-62
levels in smokers vs. nonsmokers,
4:61-62
HOMOGENIZED LEAF CURING
(See also TOBACCO CURING)
effect on smoking quality, 14:19
effect on tobacco leaf components,
14:27-28
HORMONES
antidiuretic, effect of nicotine on
secretion, 12:37
corticosteroids, effect of smoking on
secretion, 12:37, 12:40
effect of cessation of smoking,
15:23-24
effect of smoking, 15:20
in establishing smoking habit, 15:10
in maintenance of smoking habit, 15-
20
HOSPITAL ADMISSION RATES
children, maternal smoking and,
11:33
smokers vs. nonsmokers vs. ex-smok-
ers, 3:14-16
HOSPITALS
smoking policies, 22:20-23
HUMECTANTS
effect on smoke constituents, 14:29
levels in mainstream cigarette smoke,
14:68
HYDRAZINES
levels in cigarette smoke, 14:41
HYDROGEN CYANIDE
(See also CYANIDES)
cardiovascular diseases and, 4:62
occupational hazards, 7:7-8
pharmacology, 7:8
HYPERGLYCEMIA
induced by nicotine in cats, 14:90
HYPERKINESIS
carbon monoxide in animal model,
8:65
maternal smoking and, 8:23
HYPEROXIA
effect on atherosclerosis, 4:17
HYPERTENSION
(See also BLOOD PRESSURE)
biological control mechanisms, 4:56-
57
cardiovascular and cerebrovascular
diseases and, 4:57
myocardial infarct and, 4:20

nicotine and, 14:79
research needs, 4:58
school health education program,
21:21
smokers vs. nonsmokers, 4:57
HYPERSENSITIVITY
(See also ALLERGY)
basic mechanisms, 10:15
classification, 10:9
HYPNOSIS
in smoking cessation, 19:17, 19:26
HYPOXIA
effect of carbon monoxide in sheep
fetus, 8:63-65
effect on atherosclerosis, 4:17
effect on myocardium, 4:20
fetal, effect of maternal smoking,
8:17
fetal mortality and, research needs,
8:75
fetal response in sheep, 8:64

Illinois Antismoking Education Study
See UNIVERSITY OF ILLINOIS
ANTISMOKING EDUCATION
STUDY

IMIPRAMINE

effect of smoking on pharmacokinet-
ics, 12:33

IMMUNE SYSTEM

B and T lymphocytes in smokers vs.
nonsmokers, 6:31

effect of cigarette smoke in rabbits,
10:18

effect of cigarette smoke on anti-
body response in mice, 12:59

effect of cigarette smoke on humoral
immunity in mice, 10:18

effect of smoking, 10:14-20

effect of smoking on lymphocytes,
10:17

effect of smoking, summary of find-
ings, 1:18-19, 1:23-24, 1:26

effect. of smoking on cellular ele-

ments, 10:20
effect of tobacco smoke, 6:30-31,
10:5

hyperresponsiveness in smokers, 10:20
response to viral vaccines in smokers
vs. nonsmokers, 12:58-59
INFANT MORTALITY

(See also MORTALITY RISK;
NEONATAL MORTALITY; PERI-
NATAL MORTALITY)
birth weight in smoking vs. non-
smoking mothers and, 8:29
black vs. white smoking mothers,
8:28, 8:30
British Perinatal Mortality Study,
8:29
Collaborative Perinatal Study of the
NINCDS (1959-1966), 8:30
effect of maternal smoking, 8:10,
8:28, 8:32, 8:34-35
effect of maternal smoking, age,
parity, and education, 8:29-31,
8:33
effect of maternal smoking and ges-
tational age, 8:43
effect of maternal smoking and pre-
term delivery, 8:42
etiology of perinatal death in smok-
ers vs. nonsmokers, 8:36-38
maternal smoking levels and, 8:35,
8:39-40
Ontario Perinatal Mortality Study,
8:33-35
prospective and retrospective studies,
8:29
synergism of maternal smoking and
other risk factors, 8:35

INFANTS

(See also SMOKING, MATERNAL)
breastfed, effect of maternal smok-
ing, 8:51
effect of maternal smoking on birth
weight, 8:12-13
effect of maternal smoking on body
height, 8:19

INFECTIOUS DISEASES

(See also RESPIRATORY TRACT
INFECTIONS)
in smoking vs. nonsmoking pregnant
women, 10:19

INFLUENZA

(See also RESPIRATORY TRACT
INFECTIONS)
incidence in smokers vs. nonsmokers,
10:19

INITIATION OF SMOKING

age and, 17:7
behavioral factors, 16:5--13

developmental and social psychology,
17:9-12
medical students, 22:18
psychoanalytic theory, 17:10-11
psychosocial factors in adolescence,
17:12-17
INTELLECTUAL DEVELOPMENT
(See also LEARNING)
effect of maternal smoking on chil-
dren, 1:21, 8:21-23
INTERMITTENT CLAUDICATION
effect of carbon monoxide, 4:54
smoking and, 4:53-54
INTERNATIONAL ATHEROSCLERO-
SIS PROJECT
atherosclerosis risk factors, 4:8
summary of epidemiological data, 4:7
INVOLUNTARY SMOKING
absorption of nicotine by nonsmokers,
11:24
absorption of tobacco constituents by
nonsmokers, 11:6
allergy and, 11:31
asthma and, 10:21
effect of psychological factors on
physiologic response, 11:27
effect on angina pectoris patients,
11:30-31
effect on carboxyhemoglobin levels,
11:21, 11:28
effect on cardiac patients, 11:29-30
effect on children with respiratory
diseases, 11:32
effect on fetus and breastfed in-
fants, 8:51
effect on heart rate and blood pres-
sure in children, 11:27
effect on lung function in asthmatic
patients, 10:22
effect on nonsmokers, 10:12 11-5,
11:15, 11:28
effect on respiratory tract infections
in infants, 8:45
effect on skin temperature, 11:27
health effects, 21:17
health effects, summary of findings,
1:24-25
research goals, 11:35
Inspiratory reserve volume measure-
ments
See RESPIRATORY FUNCTION
TESTS
IODINE
blood levels in smokers vs. nonsmok-
ers, 12:84
ISCHEMIA
(See also CARDIOVASCULAR
DISEASES; CORONARY HEART
DISEASE)
effect of carbon monoxide and nico-
tine, 4:39
effect on myocardium, 4:19-20
in myocardial infarct etiology, 4:19-
20, 4:39-40
sudden cardiac death and, 4:43
ISOPRENOIDS
structural formulae, 14:50
in tobacco, 14:48-49

KETONES
content in cigarette smoke, 14:42
formation from humectants, 14:63
KIDNEY NEOPLASMS, 5:47-49
mortality and risk ratios in smokers,
5:48-49
smoking and, summary of findings,
1:17
KIDNEYS
organ weight in smokers vs. non-
smokers, 12:9
KIWANIS CLUB
youth-to-youth antismoking program,
20:15
KNOW YOUR BODY PROGRAM
antismoking education component,
20:11
description, 21:20

LACTATION
(See also BREAST FEEDING)
effect of maternal smoking, 8:50
effect of maternal smoking, summa-
ry of findings, 1:22
effect of nicotine in animals, 8:49
and maternal smoking, research

needs, 8:78-79
in smoking vs. nonsmoking mothers,
8:48

LARYNGEAL NEOPLASMS
(See also RESPIRATORY TRACT
NEOPLASMS)
animal models, 5:34-35
aryl hydrocarbon hydroxylase induci-
bility and, 5:57
asbestos and smoking and, 5:34
cigar and pipe smoking and, summa-
ry of findings, 1:27
effect of alcohol consumption and
smoking on risk, 5:32, 5:34
effect of cessation of smoking on
risk, 5:34, 5:37-38
effect of filters on risk, 5:34-36
effect of smoking duration on risk,
5:34
effect of smoking levels on risk,
5:33-36
induced by benzo(a)pyrene in ham-
sters, 5:34-35
induced by cigarette smoke in ham-
sters, 5:34-35
morbidity and mortality in cigar vs.
cigarette vs. pipe smokers, 13:24
mortality ratio in cigar vs. cigarette
vs. pipe smokers, 13:24
mortality ratio in smokers, 5:32-33
radiation and smoking and, 12:90
smoking and, summary of findings,
1:16-17
LEAD
(See also METALS)
levels in smokers vs. nonsmokers,
12:73
smoking and occupational exposure,
a7
LEAD-210
levels in cigarette smoke, 14:60
as tobacco contaminant, 14:20-21
LEARNING
(See also INTELLECTUAL DE-
VELOPMENT)
effect of smoking, 15:18-19
smokers vs. nonsmokers, 15:19
LEGISLATION
Federal adult education laws, 21:7
minors’ purchase and use of tobacco,
23:7-8
National Consumer Health Informa-
tion Act of 1976, 21:10
ordinances restricting smoking in
public places, 21:18